TGFB1 and cancer: VPA reverses epigenetic alterations, while simvastatin inhibits the mevalonate pathway; together, they target cancer stem cells, suppress YAP signaling, and reverse TGF-β–driven epithelial–mesenchymal transition—mechanisms shown to sensitize pancreatic tumors to chemotherapy.